Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
127.58
-6.77 (-5.04%)
At close: May 11, 2026, 4:00 PM EDT
131.25
+3.67 (2.88%)
After-hours: May 11, 2026, 7:57 PM EDT
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
1,433.54
Revenue / Employee
$11,818
Employees
110
Market Cap
1.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.30M | 1.10M | 550.00% |
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 509.86M |
| Aurinia Pharmaceuticals | 298.30M |
| AnaptysBio | 234.60M |
| Syndax Pharmaceuticals | 217.17M |
| Ascentage Pharma Group International | 82.08M |
| Intellia Therapeutics | 67.67M |
| Taysha Gene Therapies | 7.47M |
| Oculis Holding AG | 1.51M |
INBX News
- 11 hours ago - Inhibrx’s INBRX-106 shows potential benefit in HNSCC - TheFly
- 15 hours ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 15 hours ago - This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. - Barrons
- 16 hours ago - Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy - PRNewsWire
- 3 days ago - Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC - PRNewsWire
- 17 days ago - Inhibrx initiated with an Outperform at LifeSci Capital - TheFly
- 19 days ago - Inhibrx price target raised to $300 from $150 at Stifel - TheFly
- 19 days ago - Inhibrx trading halted, volatility trading pause - TheFly